United States Chronic Obstructive Pulmonary Disease (COPD) Biologics Market Growth 2025 | Set for Strong Investments

chronic obstructive pulmonary disease (COPD) biologics market size reached US$ 604.70 million in 2024 is expected to reach US$ 1,678.90 million by 2033, growing at a CAGR of 12.1% during the forecast period 2025-2033.

DataM Intelligence has published a new research report on "Chronic Obstructive Pulmonary Disease (COPD) Biologics Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

According to the British Lung Foundation, COPD is the second most common lung disease in the UK, affecting 1.2 million people and costing approximately £1.8 million annually.

In Germany, as of 2024, chronic obstructive pulmonary disease (COPD) remains a major public health issue, with about 5.8% of adults aged 18 and above reporting the condition. The prevalence increases notably with age, impacting nearly 8.5% of individuals aged 45 and older, with similar rates observed among men and women.

In Japan, data from the Ministry of Health, Labour and Welfare (MHLW) indicates that COPD prevalence ranges from 0.2% to 0.4% of the total population. However, the NICE study suggests a much higher rate of 8.6% among adults aged 40 and above. The study also revealed a low diagnosis rate, with only 9.4% of individuals with airflow obstruction formally diagnosed.

Similarly, in France, the prevalence of COPD is estimated at 2.6 million cases and is projected to increase to 2.8 million by 2025.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/chronic-obstructive-pulmonary-disease-copd-biologics-market?kb

Key Highlights

North America led the chronic obstructive pulmonary disease (COPD) biologics market, accounting for the largest revenue share of 43.5% in 2024.

The Asia-Pacific region emerged as the fastest-growing market, projected to expand at a CAGR of 8.1% during the forecast period.

By drug class, the Dupilumab segment dominated the market, capturing the largest revenue share of 54.1% in 2024.

Key Players:

Sanofi, Regeneron Pharmaceuticals, and GSK

Key Development:

In July 2025, the American Lung Association launched a new initiative to support and empower individuals living with chronic obstructive pulmonary disease (COPD), with a focus on rural and underserved communities across the U.S. COPD affects an estimated 16 million Americans and is characterized by chronic, progressive airflow limitation that makes breathing difficult.

In September 2024, the U.S. Food and Drug Administration (FDA) approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with COPD who remain inadequately controlled and have an eosinophilic phenotype. This marks the first FDA-approved biologic treatment in the U.S. for this specific patient group.

Growth Forecast Projected:

The Global Chronic Obstructive Pulmonary Disease (COPD) Biologics Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Chronic Obstructive Pulmonary Disease (COPD) Biologics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=chronic-obstructive-pulmonary-disease-copd-biologics-market?kb

Key Segments:

Drug Class: (Dupilumab, Mepolizumab)

By Route of Administration: (Subcutaneous)

By Distribution Channel: (Hospital Pharmacies, Specialty Pharmacies)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Chronic Obstructive Pulmonary Disease (COPD) Biologics producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Chronic Obstructive Pulmonary Disease (COPD) Biologics revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/chronic-obstructive-pulmonary-disease-copd-biologics-market?kb

FAQ's

Q1: How fast is the Chronic Obstructive Pulmonary Disease (COPD) Biologics Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 12.1% from 2025 to 2032

Q2: Which regions are dominating the Chronic Obstructive Pulmonary Disease (COPD) Biologics Market and which are fastest-growing?

A: North America led the global COPD biologics market, holding 43.5% of the share in 2024.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/chronic-obstructive-pulmonary-disease-copd-biologics-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.